Venoruton® (Venoruton® )

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsptablets, effervescent
Composition:

Each effervescent tablet contains:

Active substance: hydroxyethylrutosides * 1000.00 mg.

Excipients: citric acid * 1775.00 mg, potassium carbonate 460.00 mg, potassium, hydrogen carbonate 320.00 mg, sodium hydrogen carbonate 300.00 mg, macrogol-6000 70.00 mg, acesulfame potassium 60.00 mg, povidone 40.00 mg, flavor, orange PHS-140561 24.00 mg, magnesium stearate 1.00 mg.

* volume is adjusted depending on the titer of the active substance

Description:

Round tablets of the flat-cylindrical form of yellow color with a facet, a rough surface with impregnations and an orange smell.

Pharmacotherapeutic group:Angioprotective agent
ATX: & nbsp
  • Rutozid
    • Pharmacodynamics:

    Derivative routine. Acts mainly on capillaries and veins. Strengthens the walls of blood vessels and increases their tone. Helps improve blood circulation.

    Reduces the pores between endothelial cells by modifying a fibrous matrix located between endothelial cells.

    Inhibits aggregation and increases the degree of erythrocyte deformability, renders anti-inflammatory effect.

    With chronic venous insufficiency, Venoruton® reduces the severity of edema, pain, seizures, trophic disorders, varicose ulcers.

    It alleviates the symptoms associated with hemorrhoids: pain, itching and bleeding.

    Due to the beneficial effect of Venoruton® on the permeability and resistance of the capillary walls, the drug - promotes the retardation of the development of diabetic retinopathy. In addition, the effect of Venoruton® on the rheological properties of blood contributes to the prevention of retinal microtrombosis.

    Pharmacokinetics:

    After oral administration, the maximum concentration in the blood plasma is achieved for 2-9 hours. Within 40 h the concentrationthe drug remainsmy, its decline is going onnot necessarily.

    Binding to plasma proteins is 27-29%. Hydroxyethyl rutozides and their glucuronidated metabolitesmainly with bile, 3-6% are excreted by the kidneys for 48 hours. The period of the sexremoval of hydroxyethylrutosides can vary from 13.5 to 25.7 hours, but each person its value relative tois constant.

    Indications:

    • Chronic venous insufficiency, post-phlebitic syndrome, trophic disorders in varicose veins and trophic ulcers with symptoms such as edema, pain, cramps, paresthesia and a feeling of heaviness in the legs.
    • As an auxiliary treatment for lymphostasis, after sclerotherapy of veins and removal of varicose veins.
    • Hemorrhoids (pain, exudation, itching and bleeding).
    • As an auxiliary treatment for retinopathy in patients with sugar Diabetes, arterial hypertension and atherosclerosis.

    Contraindications:

    Hypersensitivity to rutozides or to other components of the drug.

    Pregnancy (I trimester), children under 18 years.

    Carefully:
    Pregnancy and lactation:

    In experimental studies, there were no teratogenic or other adverse effects on the fetus. With breast milk, only small amounts of the drug are released, which is not of clinical significance. Intended use of Venoruton® in pregnancy with the second trimester, and also during lactation is possible if the expected benefit for the mother exceeds the possible risk to the fetus.

    Dosing and Administration:

    Inside with food. Before use, the tablet is dissolved in a glass of cooled boiled water.

    When chronic venous insufficiency, post-phlebitic syndrome, trophic disorders in varicose veins and trophic ulcers: at the initial stage of treatment (during the first 2 weeks) take 1 effervescent tablet of Venoruton ® once a day.Further treatment is either continued for 2-3 months at the same dose as maintenance therapy, or discontinued. At the same time, the achieved therapeutic effect is maintained for at least 4 weeks. The minimum course of treatment, during which the effect usually develops, is 2 weeks.

    To maintain results, it is necessary to carry out 2 courses of treatment per year.

    With lymphostasis (along with bandaging of elastic bandages), also after sclerotherapy of veins and removal of varicose veins: the recommended daily dose is 1x effervescent tablet 3 times a day (no more than 3 tablets per day) for up to 6 months.

    To eliminate symptoms of hemorrhoids: for 1 effervescent tablet 1 time per day until symptoms are eliminated, usually within 28 days.

    With retinopathy, patients with diabetes mellitus, arterial hypertension, and atherosclerosis (as an auxiliary therapy): recommended daily dose is 1x effervescent tablet 2-3 times a day, not more than 3000 mg per day, for 2 months.

    Side effects:

    Disorders from the immune system:

    very rarely (<1/10000): anaphylactoididiotic reactions, hypersensitivity reactionsviability.

    Disorders from the nervous system:

    very rarely (<1/10000): dizziness, headache.

    Vascular disorders:

    very rarely (<1/10000): "tides" of blood to face.

    Disorders from the organs of the dietrhenium:

    rarely (> 1/10 000, <1/1000): the gastrointestinal tract,intestinal disorders, bloating, Diarrhea, abdominal pain, sensationdiscomfort in the stomach, racesdigestion system.

    Skin and subcutaneous tissues:

    rarely (> 1/10 000, <1/1000): skin rash, itching, hives.

    General disorders: very rarely (<1/10 000): weakness.

    Overdose:

    No cases of overdose accompanied by clinical symptoms have been reported.

    Interaction:

    The action is enhanced by simultaneous intake of ascorbic acid.

    Special instructions:

    If during the period of drug use the severity of the symptoms of the disease is not decreases, should be consultedwith the doctor.

    Effect on the ability to drive transp. cf. and fur:

    It was not reported on the effect of the drug on the ability to drive and work with machinery.

    Form release / dosage:

    Effervescent tablets 1 g.

    Packaging:For 15 tablets in a polypropylene case with a polyethylene plug containing a desiccant silica gel equipped with a first-opening control system.The pencil case together with the instruction for use is placed in a cardboard box.
    Storage conditions:

    In a dry place at a temperature of no higher than 30 ° C. Store in a tightly ukuporennoy pack. Keep out of the reach of children.

    Shelf life:

    4 years. Do not use after the expiry date indicated on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LS-000655
    Date of registration:08.07.2011
    Expiration Date:Unlimited
    The owner of the registration certificate:Новартис Консьюмер Хелс САНовартис Консьюмер Хелс СА Switzerland
    Manufacturer: & nbsp
    Representation: & nbspNovartis Consumer Helms Ltd.Novartis Consumer Helms Ltd.
    Information update date: & nbsp25.01.2017
    Illustrated instructions
      Instructions
      Up